Primary sclerosing cholangitis: Diagnosis and management

Current Gastroenterology Reports

Volumn 8, Issue 1, 2006, Pages 75-82

  Charatcharoenwitthaya, Phunchai ^b   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCIUM; CARBOHYDRATE ANTIGEN; CLADRIBINE; COLCHICINE; COLESTYRAMINE; CYCLOSPORIN; ETANERCEPT; FLUVOXAMINE; GLUCOCORTICOID; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINE; OPIATE ANTAGONIST; PENICILLAMINE; PENTOXIFYLLINE; PIRFENIDONE; PLACEBO; PREDNISOLONE; RIFAMPICIN; SILYMARIN; TSUKUBAENOLIDE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VITAMIN D;

AGE; ALKALINE PHOSPHATASE BLOOD LEVEL; AUTOIMMUNE DISEASE; BILE DUCT CARCINOMA; CHOLANGIOGRAPHY; CLINICAL FEATURE; CLINICAL TRIAL; COLON CANCER; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG MEGADOSE; DRUG RESPONSE; FATIGUE; GALLBLADDER TUMOR; GENETIC SUSCEPTIBILITY; HEPATIC DUCT; HEPATOBILIARY SYSTEM; HUMAN; IMMUNE DYSREGULATION; INTRAHEPATIC BILE DUCT; LIVER TRANSPLANTATION; LYMPHOCYTE HOMING; METABOLIC BONE DISEASE; PATHOPHYSIOLOGY; PATIENT CARE; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; PRURITUS; REVIEW; SEX DIFFERENCE; STANDARDIZATION; TREATMENT INDICATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

AUTOIMMUNE DISEASES; CHOLAGOGUES AND CHOLERETICS; CHOLANGIOGRAPHY; CHOLANGITIS, SCLEROSING; COLITIS, ULCERATIVE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LYMPHOCYTES; MALE; PROGNOSIS; RECURRENCE; URSODEOXYCHOLIC ACID;

EID: 33645046641     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-006-0067-8     Document Type: Review

References (75)

1. Boberg KM, Aadland B, Jahnsen J, et al.: Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998, 33:99-103.
2. Bambha K, Kim WR, Talwalkar J, et al.: Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003, 125:1364-1369.
3. Kingham JG, Kochar N, Gravenor MB: Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004, 126:1929-1930.
4. Bergquist A, Lindberg G, Saarinen S, et al.: Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol 2005, 42:252-256.
5. Lawson A, West J, Aithal GP, et al.: Autoimmune cholestatic liver disease in people with coeliac disease: a population-based study of their association. Aliment Pharmacol Ther 2005, 21:401-405.
6. Talwalkar JA, Lindor KD: Primary sclerosing cholangitis. Inflamm Bowel Dis 2005, 11:62-72.
7. Aoki CA, Bowlus CL, Gershwin ME: The immunobiology of primary sclerosing cholangitis. Autoimmun Rev 2005, 4:137-143.
8. Feldstein AE, Perrault J, El-Youssif M, et al.: Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003, 38:210-217.
9. Nakazawa T, Ohara H, Sano H, et al.: Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. Gastrointest Endosc 2004, 60:937-944.
10. Resnick D, Krinsky GA, Lavelle MT, et al.: Do patients with primary sclerosing cholangitis have a greater frequency of pancreatic abnormalities at MRI than patients with other liver diseases? J Comput Assist Tomogr 2002, 26:994-999.
11. Angulo P, Pearce DH, Johnson CD, et al.: Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis. J Hepatol 2000, 33:520-527.
12. Textor HJ, Flacke S, Pauleit D, et al.: Three-dimensional magnetic resonance cholangiopancreatography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography. Endoscopy 2002, 34:984-990.
13. Talwalkar JA, Angulo P, Johnson CD, et al.: Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology 2004, 40:39-45.
14. Silva AC, Friese JL, Hara AK, et al.: MR cholangiopancreatography: improved ductal distention with intravenous morphine administration. Radiographics 2004, 24:677-687.
15. Macchi V, Floreani A, Marchesi P. et al.: Imaging of primary sclerosing cholangitis: preliminary results by two new non-invasive techniques. Dig Liver Dis 2004, 36:614-621.
16. Hirche TO, Russler J, Braden B, et al.: Sonographic detection of perihepatic lymphadenopathy is an indicator for primary sclerosing cholangitis in patients with inflammatory bowel disease. Int J Colorectal Dis 2004, 19:586-594.
17. Burak KW, Angulo P, Lindor KD: Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol 2003, 98:1155-1158.
18. Angulo P. Maor-Kendler Y, Lindor KD: Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology 2002, 35:1494-1500.
19. Bjornsson E, Boberg KM, Cullen S, et al.: Patients with small duct primary sclerosing cholangitis have a favorable long term prognosis. Gut 2002, 51:731-735.
20. Kaya M, Angulo P, Lindor KD: Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000, 33:537-42.
21. Gheorghe L, Iacob S, Gheorghe C, et al.: Frequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease. Eur J Gastroenterol Hepatol 2004, 16:585-592.
22. Floreani A, Rizzotto ER, Ferrara F, et al.: Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005 100:1516-1522.
23. Zein CO, Lindor KD, Angulo P: Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology 2004, 39:204-210.
24. Bjornsson E, Simren M, Olsson R, et al.: Fatigue in patient with primary sclerosing cholangitis. Scand J Gastroenterol 2004, 39:961-8.
25. ter Borg PC, van Os E, van den Broek WW, et al.: Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]. BMC Gastroenterol 2004, 4:1-13.
26. Epstein MP, Kaplan MM: A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2004, 49:1-4.
27. Campbell MS, Lichtenstein GR, Rhim AD, et al.: Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis. Liver Int 2005, 25:311-316.
28. Kaya M, Petersen BT, Angulo P, et al.: Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 2001, 96:1059-1066.
29. Bjornsson E, Lindqvist-Ottosson J, Asztely M, et al.: Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 2004, 99:502-508.
30. Stiehl A, Rudolph C, Kloters-Plachky P, et al.: Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002, 36:151-156.
31. Vuddagiri SK, France R, Kozarek R: Endoscopic therapy in primary sclerosing cholangitis (PSC): does the complication risk outweigh therapeutic benefit? [abstract]. Gastrointest Endosc 2004: 59:AB193.
32. Burak K, Angulo P, Pasha TM, et al.: Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004, 99:523-526.
33. Brandsaeter B, Isoniemi H, Broome U, et al.: Liver transplantation for primary sclerosing cholangitis, predictors and consequences of hepatobiliary malignancy. J Hepatol 2004, 40:815-822.
34. Levy C, Lymp J, Angulo P, et al.: The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005, 50:1734-1740.
35. Lindberg B, Arnelo U, Bergquist A, et al.: Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis. Endoscopy 2002, 34:909-916.
36. Knopmann J, Thuluvath PJ, Zahurak ML, et al.: Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 2004, 101:1609-1615.
37. Berr F: Photodynamic therapy for cholangiocarcinoma. Semin Liver Dis 2004, 24:177-187.
38. Abu-Hamda EM, Baron TH: Endoscopic management of cholangiocarcinoma. Semin Liver Dis 2004, 24:165-175.
39. Buckles DC, Lindor KD, Larusso NF, et al.: In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol 2002, 97:1138-1142.
40. Loftus EV Jr, Harewood GC, Loftus CG, et al.: PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005, 54:91-96.
41. Pardi DS, Loftus EV Jr, Kremers WK, et al.: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889-893.
42. Stahlberg D, Veress B, Tribukait B, et al.: Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study. Dis Colon Rectum 2003, 46:770-778.
43. Vera A, Gunson BK, Ussatoff V, et al.: Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 2003, 75:1983-1988.
44. Beuers U, Spengler U, Kruis W, et al.: Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992, 16:707-714.
45. Stiehl A, Walker S, Stiehl L, et al.: Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994, 20:57-64.
46. Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997, 336:691-695.
47. van Hoogstraten HJ, Wolfhagen FH, van de Meeberg PC, et al.: Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol 1998, 29:417-423.
48. Rost D, Rudolph G, Kloeters-Plachky P, et al.: Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 2004, 40:693-698.
49. Mitchell SA, Bansi DS, Hunt N, et al.: A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001, 121:900-907.
50. Harnois DM, Angulo P, Jorgensen RA, et al.: High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001, 96:1558-1562.
51. Olsson RG, Boberg KM, Schaffalitzky de Muckadel O, et al.: Five year treatment with high dose UDCA in PSC [abstract]. J Hepatol 2004, 40:161.
52. LaRusso NF, Wiesner RH, Ludwig J, et al.: Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988, 95:1036-1042.
53. Olsson R, Broome U, Danielsson A, et al.: Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995, 108:1199-1203.
54. Knox TA, Kaplan MM: A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994, 106:494-499.
55. Sandborn WJ, Wiesner RH, Tremaine WJ, et al.: Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut 1993, 34:242-246.
56. Vleggaar UP, van Buuren HR, van Berge Henegouwen GP, et al.: No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study. Eur J Gastroenterol Hepatol 2001, 13:171-175.
57. Bharucha AE, Jorgensen R, Lichtman SN, et al.: A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000, 95:2338-2342.
58. Angulo P, Jorgensen R, Keach J, et al.: Silymarin in the treatment of patients with primary sclerosing cholangitis. Gastroenterology 2001, 120(Suppl.1):A353.
59. Angulo P, Bharucha AU, Jorgensen RA, et al.: Oral nicotine intreatment of primary sclerosing cholangitis: a pilot study. Dig Dis Sci 1999, 44:602-607.
60. Angulo P, MacCarty RL, Sylvestre PB, et al.: Pirfenidone in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2002, 47:157-161.
61. van Hoogstraten HJ, Vleggaar FP, Boland GL, et al.: Budesonide or prednisone in combination with ursodeozycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol 2000, 95:2015-2022.
62. Angulo P, Batts KP, Jorgensen RA, et al.: Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000, 95:2333-2337.
63. Duchini A, Younossi ZM, Saven A, et al.: An open-label pilot trial of cladibrine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. J Clin Gastroenterol 2000, 31:292-296.
64. Talwalkar JA, Angulo P, Keach JC, et al.: Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2005, 39:168-171.
65. Chen W, Gluud C: Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst Rev 2004, (3):CD004036.
66. Van Thiel DH, Carroll P, Abu-Elmagd K, et al.: Tacrolimus (UK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995, 90:455-459.
67. Schramm C, Schirmacher P. Helmreich-Becker I, et al.: Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med 1999, 131:943-946.
68. Lindor KD, Wiesner RH, Colwell LJ, et al.: The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 1991, 86:57-61.
69. Lindor KD, Jorgensen RA, Anderson ML, et al.: Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol 1996, 91:511-515.
70. Sterling RK, Salvatori JJ, Luketic VA, et al.: A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Aliment Pharmacol Ther 2004, 20:943-949.
71. Farkkila M, Karvonen AL, Nurmi H, et al.: Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004, 40:1379-1386.
72. Brandsaeter B, Friman S, Broome U, et al.: Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol 2003, 38:1176-1183.
73. Vera A, Moledina S, Gunson B, et al.: Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002, 360:1943-1944.
74. Kugelmas M, Spiegelman P, Osgood MJ, et al.: Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2003, 9:727-732.
75. Maheshwari A, Too HY, Thuluvath PJ: Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol 2004, 99:538-542.